drugset / Trial / NCT04065698

Pharmacokinetics and Safety of RV521 Formulations

NCT04065698

Phase 1 Completed 9 enrolled Pfizer
NaSingle-groupOpen-labelOther

Summary

The main aims of the study are to assess the pharmacokinetics and safety of single doses of RV521 administered as two different formulations

Timeline

Start
2019-08-13
Primary completion
2019-09-02
Completion
2019-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject sisunatovir Small molecule 200 mg Oral